My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
GlycoMimetics (GLYC)
NASDAQ:GLYC
GLYC nasdaq
United States
GlycoMimetics

GlycoMimetics Stock Analysis & Ratings

GlycoMimetics Stock Analysis Overview

Smart Score
2
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The GlycoMimetics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

GLYC

GLYC Stock Stats

Previous Close$2.03
Open$2.04
Bid1.91 x 11
Ask2.2 x 110
Today’s Range$1.97 - $2.04
52-Week Range$1.78 - $4.40
Volume259.40K
Average Volume654.78K
Market Cap$102.05M
Beta2.03
P/E Ratio-1.7
EPS-1.18
Earnings DateNov 11, 2021

Company Description

GlycoMimetics

GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
Sector
Healthcare
Industry
Biotechnology
CEO
Harout Semerjian
Employees
54
ISIN
US38000Q1022
Address
9708 Medical Center Drive, Rockville, MD, 20850, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

GLYC FAQ

What was GlycoMimetics’s price range in the past 12 months?
GlycoMimetics lowest stock price was $1.78 and its highest was $4.40 in the past 12 months.
    What is GlycoMimetics’s market cap?
    GlycoMimetics’s market cap is $102.05M.
      What is GlycoMimetics’s price target?
      The average price target for GlycoMimetics is $14.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $14.00 ,the lowest forecast is $14.00. The average price target represents 607.07% Increase from the current price of $1.98.
        What do analysts say about GlycoMimetics?
        GlycoMimetics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is GlycoMimetics’s upcoming earnings report date?
          GlycoMimetics’s upcoming earnings report date is Nov 11, 2021 which is in 23 days.
            How were GlycoMimetics’s earnings last quarter?
            GlycoMimetics released its earnings results on Aug 05, 2021. The company reported -$0.279 earnings per share for the quarter, beating the consensus estimate of -$0.308 by $0.029.
              Is GlycoMimetics overvalued?
              According to Wall Street analysts GlycoMimetics’s price is currently Undervalued.
                Does GlycoMimetics pay dividends?
                GlycoMimetics does not currently pay dividends.
                What is GlycoMimetics’s EPS estimate?
                GlycoMimetics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does GlycoMimetics have?
                GlycoMimetics has 51,540,000 shares outstanding.
                  What happened to GlycoMimetics’s price movement after its last earnings report?
                  GlycoMimetics reported an EPS of -$0.279 in its last earnings report, beating expectations of -$0.308. Following the earnings report the stock price went up 4.569%.
                    Which hedge fund is a major shareholder of GlycoMimetics?
                    Among the largest hedge funds holding GlycoMimetics’s share is Moore Capital Management LP. It holds GlycoMimetics’s shares valued at N/A.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis